Q&A

Jesse H. Wright, MD, PhD reflects on his groundbreaking contributions to cognitive behavior therapy and the evolution of psychiatric education over 5 decades.

New research reveals ketamine's safe use for treating eating disorders, offering hope for patients with comorbid treatment-resistant depression.

Christine Yu Moutier, MD, the chief medical officer of the AFSP, speaks about the impact of losing LGBTQ+ tailored crisis support via 988, and strategies to better support vulnerable youth.

Innovative digital therapeutics like CT-155 are transforming mental health treatment, targeting negative symptoms of schizophrenia and enhancing depression care. Check out this conversation with Shaheen Lakhan, MD, PhD.

Vincenzo Di Nicola discusses the importance of pluralism in social psychiatry and the need for culturally relevant psychotherapy at the 2025 APA Annual Meeting.

Badr Ratnakaran, MBBS, Psychiatric Times' new Climate Change Section Editor, explores the intersection of climate change and mental health, highlighting the urgent need for awareness and support in clinical practice.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Dr Sue Varma shares her journey in psychiatry and media, promoting practical optimism and combating misinformation in mental health discussions.

A pioneer in cognitive behavior therapy shares his thoughts on a 50-year-long career.

Vincenzo Di Nicola has won the Award for Leadership in Child, Adolescent, and Young Adult Psychiatry. Learn more about his thoughts on trauma, leadership, and issues in child and adolescent psychiatry.

The president of Black Psychiatrists of America shares his thoughts on making a difference for Black communities, the removal of the REMS for clozapine, and more.

How can you provide comprehensive care in underserved environments, particularly for individuals with complex mental health needs? Amitha Dhingra, MD, weighs in.

Judith S. Beck, PhD, and Janeé M. Steele, PhD, engage in a conversation about how clinicians from all backgrounds can address issues of race in session and also empower Black patients with a sense of personal pride in their identities.

Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA.

Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.

Learn more about how cognitive behavior therapy can be used as a healing tool in marginalized communities.

With art we build what poverty destroys.

A therapist asks a question that makes me glimpse the eternal.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?

Art informs life and life informs art.

Art imitates life imitates art.

How are eating disorders different in LGBTQ+ patients compared with cisgender heterosexual patients? How can you best help manage eating disorders in this patient population?

Psychiatric Times asked H. Steven Moffic, MD, to share his thoughts on humanitarianism and psychiatry.

What does being a humanitarian mean to H. Steven Moffic, MD, winner of the 22024 Abraham L. Halpern Humanitarian Award?

Transgender individuals are 4 times as likely as their cisgender peers to have a mental illness. Check out these culturally competent care strategies and tips to provide the best possible care.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

What questions did a Milwaukee community of older adults have for a psychiatrist?

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.